http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The prognostic value of tumor budding in gastric adenocarcinomas: A cross-sectional study
Baydas Tuba,Coban Ganime,Besiroglu Mehmet,Simsek Melih,Shbair Abdallah TM,Topcu Atakan,Yasin Ayse Irem,Seker Mesut,Turk Haci Mehmet 소화기인터벤션의학회 2023 International journal of gastrointestinal interven Vol.12 No.2
Background: Tumor budding is a negative prognostic factor for many solid malignancies. We investigated the relationship between patients’ clinico-pathological characteristics and tumor budding, as well as the effect of budding level on prognosis. Methods: In this retrospective, cross-sectional, and descriptive study at a tertiary university hospital, 104 patients with gastric adenocarcinoma were divided into two groups according to whether they had a high (≥ 10 buds) or low (< 10 buds) level of budding. The patients were retrospectively evaluated.Results: Sixty-two patients had a low level of budding and 42 had a high level of budding. The mean time from the first diagnosis to the last follow-up was significantly longer (P < 0.05) in the low-budding group (27 months) than in the high-budding group (17 months). As the T stage, N stage, grade, and size of the tumor increased, the proportion of patients with high budding was found to be significantly higher (P < 0.05). High tumor budding, an age of 60 or over at diagnosis, a low body mass index, high N stage, presence of lymphovascular invasion, and recurrence were associ-ated with overall survival.Conclusion: Our study supports that budding is a negative prognostic factor in gastric cancer.
Duran, Ayse Ocak,Karaca, Halit,Besiroglu, Mehmet,Bayoglu, Ibrahim Vedat,Menekse, Serkan,Yapici, Heves Surmeli,Yazilitas, Dogan,Bahceci, Aykut,Uysal, Mukremin,Sevinc, Alper,Hacibekiroglu, Ilhan,Aksoy, Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.23
Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC).The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95%CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95%CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95%CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95%CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.
Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey
Can, Alper,Dogan, Erkan,Bayoglu, Ibrahim Vedat,Tatli, Ali Murat,Besiroglu, Mehmet,Kocer, Murat,Dulger, Ahmet Cumhur,Uyeturk, Ummugul,Kivrak, Derya,Orakci, Zuat,Bal, Oznur,Kacan, Turgut,Olmez, Sehmus,T Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.6
Background: Hepatocellular cancer (HCC) is one of the important health problems in Turkey, being very common and highly lethal. The aim of this study was to determine clinical, demographic features and risk factors. Materials and Methods: Nine hundred and sixth-three patients with HCC from 13 cities in Turkey were included in this study. Results: Only 205 (21%) of the 963 patients were women, with a male:female predominance of 4.8:1 and a median age of 61 years. The etiologic risk factors for HCC were hepatitis B in 555 patients (57.6%), 453 (81%) in men, and 102 (19%) in women, again with male predominance, hepatitis C in 159 (16.5%), (14.9% and 22.4%, with a higher incidence in women), and chronic alcohol abuse (more than ten years) in 137 (14.2%) (16.8% and 4.9%, higher in males). The Child-Pugh score paralleled with advanced disease stage amd also a high level of AFP. Conclusions: According to our findings the viral etiology (hepatitis B and hepatitis C infections) in the Turkish population was the most important factor in HCC development, with alcohol abuse as the third risk factor. The Child-Pugh classification and AFP levels were determined to be important prognostic factors in HCC patients.